Table 1.

Clinicopathological data of the EAC-patients included in the study

				HER2 expression				P value
		Total		Negative		Positive
a) Demographic and pathological results of the cohort
SEX	female	38	10.5%	34	89.5%	4	10.5%	0.333
	male	324	89.5%	284	87.70%	40	12.3%
Age group	<  65 yrs	195	53.8%	167	85.5%	28	14.5%	0.062
	>  65 yrs	167	46.1%	151	90.4%	16	9.6%
Tumor stage	pT1	33	9.1%	26	80.0%	7	20.0%	0.038
	pT2	30	8.3%	28	93.9%	2	6.1%
	pT3	287	79.2%	251	87.7%	35	12.3%
	pT4	11	3.0%	11	100.0%	0	0.0%
Lymph node metastasis	pN0	138	38.0%	113	82.5%	24	17.5%	0.02
	pN+	224	62.0%	204	91.1%	20	8.9%
Grading	G1/2	152	61.8%	126	82.9%	26	17.1%	0.009
	G3/4	94	38.2%	89	94.7%	5	5.4%
UICC	I	50	13.8%	39	78.8%	11	21.2%	0.039
	II	53	14.6%	47	89.1%	6	10.9%
	III	169	46.7%	147	86.9%	22	13.1%
	IV	89	24.6%	84	94.7%	5	5.3%
b) Cross-table analysis of the patient cohort
	Hazard ratio			95% confidence interval				P value
				Lower	Upper
SEX (female vs. male)	1.718			0.977	3.023			0.06
Age group (<  65 vs. >  65 yrs)	1.194			0.914	1.559			0.193
pT (pT1/2 vs. pT3/4)	1.331			0.982	1.804			0.065
pN (pN0 vs. pN+)	0.937			0.77	1.139			0.513
UICC (Stage I/II vs. III/IV)	1.975			1.559	2.503			0
HER2 expression (neg. vs. pos.)	0.628			0.401	0.983			0.042